Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Specials
Spring Home & Garden Show
Home & Realty
Outdoor Guide
Women
Spring on the Road
Spring Wellness
Premier Home Stylle Tour 2024
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
2024 Readersâ Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Natera, Inc.
< Previous
1
2
Next >
New Publication Demonstrates Signatera’s Ability to Risk Stratify and Detect Recurrence Early in Resected Stage I-II Lung Cancer
January 30, 2024
From
Natera, Inc.
Via
Business Wire
Tickers
NTRA
Jury Rules in Favor of Natera in Patent Infringement Lawsuit Against CareDx; Awards $96.3 Million in Damages to Natera in Lost Profits and Past Royalties
January 29, 2024
From
Natera, Inc.
Via
Business Wire
Tickers
NTRA
Nature Medicine Publishes Two Studies Highlighting Signatera’s Clinical Utility in Patients with Gastrointestinal Malignancies
January 25, 2024
From
Natera, Inc.
Via
Business Wire
Tickers
NTRA
Natera Acquires Reproductive Health Assets from Invitae
January 22, 2024
From
Natera, Inc.
Via
Business Wire
Tickers
NTRA
Natera to Present New Data from the CIRCULATE-Japan and BESPOKE CRC Studies at ASCO GI 2024 Supporting Signatera’s Clinical Utility in CRC
January 18, 2024
From
Natera, Inc.
Via
Business Wire
Tickers
NTRA
Natera Provides Update on Ravgen Trial
January 16, 2024
From
Natera, Inc.
Via
Business Wire
Tickers
NTRA
Natera Announces Preliminary Fourth Quarter and Full Year 2023 Revenues
January 09, 2024
From
Natera, Inc.
Via
Business Wire
Tickers
NTRA
Natera to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
December 29, 2023
From
Natera, Inc.
Via
Business Wire
Tickers
NTRA
Natera Wins Preliminary Injunction in Patent Infringement Lawsuit Against NeoGenomics’ RaDaR Test
December 27, 2023
From
Natera, Inc.
Via
Business Wire
Tickers
NTRA
Natera Announces New Study Highlighting the Benefits of Signatera’s Unique Method of Quantifying ctDNA
December 21, 2023
From
Natera, Inc.
Via
Business Wire
Tickers
NTRA
Delaware Court Denies CareDx’s Motion for Summary Judgment on Two Natera Patents
December 11, 2023
From
Natera, Inc.
Via
Business Wire
Tickers
NTRA
Natera Presents New Signatera™ MRD Data Across Breast Cancer Treatment Settings at SABCS 2023
December 06, 2023
From
Natera, Inc.
Via
Business Wire
Tickers
NTRA
Natera Announces Real-World Data Collaboration with Merck
November 14, 2023
From
Natera, Inc.
Via
Business Wire
Tickers
NTRA
Natera Reports Third Quarter 2023 Financial Results
November 08, 2023
From
Natera, Inc.
Via
Business Wire
Tickers
NTRA
Natera Announces Randomized, Phase III TREAT ctDNA Trial in Early-Stage Breast Cancer
November 08, 2023
From
Natera, Inc.
Via
Business Wire
Tickers
NTRA
Natera to Participate in November Investor Conferences
November 07, 2023
From
Natera, Inc.
Via
Business Wire
Tickers
NTRA
Natera’s Landmark RenaCARE Study Demonstrates Significant Diagnostic and Clinical Utility of Renasight™ in Chronic Kidney Disease
November 02, 2023
From
Natera, Inc.
Via
Business Wire
Tickers
NTRA
Updated Data from CIRCULATE-Japan Presented at ESMO 2023 Reinforces Signatera’s Prognostic and Predictive Value in Analysis of 2,500+ Colorectal Cancer Patients
October 22, 2023
From
Natera, Inc.
Via
Business Wire
Tickers
NTRA
Natera to Report its Third Quarter 2023 Results on November 8
October 20, 2023
From
Natera, Inc.
Via
Business Wire
Tickers
NTRA
Natera Recognized on U.S. News & World Report’s 2024 Best Companies to Work for in Healthcare Ranking
October 19, 2023
From
Natera, Inc.
Via
Business Wire
Tickers
NTRA
Natera to Present New Signatera™ MRD Data at ESMO 2023, Featuring Large, Updated Analysis from CIRCULATE-Japan Study
October 16, 2023
From
Natera, Inc.
Via
Business Wire
Tickers
NTRA
New MRD Publication in Unresectable Stage I-III Lung Cancer Demonstrates Signatera’s Ability to Risk Stratify and Detect Progression Early
October 04, 2023
From
Natera, Inc.
Via
Business Wire
Tickers
NTRA
Supreme Court Denies CareDx Request for Appeal in Patent Case with Natera
October 03, 2023
From
Natera, Inc.
Via
Business Wire
Tickers
NTRA
Natera Submits First PMA Module to the FDA for Signatera™
October 02, 2023
From
Natera, Inc.
Via
Business Wire
Tickers
NTRA
Natera Announces Senior Leadership Appointments
September 18, 2023
From
Natera, Inc.
Via
Business Wire
Tickers
NTRA
Natera Announces Expanded I-SPY 2 Collaboration to Evaluate Signatera™ for Breast Cancer Patients in the Neoadjuvant Setting
September 14, 2023
From
Natera, Inc.
Via
Business Wire
Tickers
NTRA
Natera Announces Pricing of $250 Million Follow-On Offering
September 07, 2023
From
Natera, Inc.
Via
Business Wire
Tickers
NTRA
Natera Launches Proposed Follow-On Offering
September 06, 2023
From
Natera, Inc.
Via
Business Wire
Tickers
NTRA
Natera to Participate in Upcoming Investor Conferences
September 01, 2023
From
Natera, Inc.
Via
Business Wire
Tickers
NTRA
Natera’s Prospera™ Lung Transplant Assessment Test Granted Medicare Coverage
August 16, 2023
From
Natera, Inc.
Via
Business Wire
Tickers
NTRA
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.